Significant Improvement Found in Clinical Trial for Dravet Syndrome


An expert describes the efficacy of fenfluramine in decreasing seizure frequency associated with this rare syndrome.

Fenfluramine proved successful in decreasing seizure frequency in a Phase 3 study of Dravet syndrome, a rare pediatric condition known for its treatment resistance.

In this podcast, Dr. Wilner interviews Arnold Gammaitoni, PharmD, about this potentially game-changing new epilepsy drug.

If these results can be duplicated, it raises the possibility of a new, effective treatment for seizures in children with Dravet syndrome.

RELATED CONTENT: Dietary Therapy to Improve Epilepsy Outcomes: Case Vignettes

More podcasts here.

Related Videos
Frederic Schaper, MD, PhD
Jaime Imitol, MD
Jason M. Davies, MD, PhD
Carolyn Bernstein, MD
Prashanth Rajarajan, MD, PhD
Mandy Alhajj, DO, James Dolbow, DO & Neel Fotedar, MD
Riley Bove, MD
Bruce Bebo, PhD
Susan W. Broner, MD
© 2024 MJH Life Sciences

All rights reserved.